Jens J Holst Selected Research

Bile Acids and Salts (Bile Acids)

3/2024	Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling.
12/2023	Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
1/2020	Postprandial Dyslipidemia, Hyperinsulinemia, and Impaired Gut Peptides/Bile Acids in Adolescents with Obesity.
1/2018	The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
1/2018	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.
11/2017	Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
12/2014	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes.
12/2013	Bile acids induce glucagon-like peptide 2 secretion with limited effects on intestinal adaptation in early weaned pigs.
1/2012	Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs.
9/2009	Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jens J Holst Research Topics

Disease

234	Type 2 Diabetes Mellitus (MODY) 05/2024 - 01/2002
92	Insulin Resistance 04/2024 - 03/2002
85	Obesity 05/2024 - 11/2003
62	Weight Loss (Weight Reduction) 02/2024 - 01/2007
56	Body Weight (Weight, Body) 01/2024 - 05/2003
42	Hypoglycemia (Reactive Hypoglycemia) 12/2023 - 03/2002
38	Hyperglycemia 09/2023 - 08/2006
36	Overweight 04/2024 - 03/2003
30	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2024 - 06/2007
27	Glucose Intolerance 01/2024 - 09/2004
18	Bone Resorption 07/2023 - 12/2003
18	Inflammation (Inflammations) 01/2023 - 03/2004
15	Short Bowel Syndrome 04/2023 - 07/2004
13	Non-alcoholic Fatty Liver Disease 01/2024 - 04/2016
11	Metabolic Diseases (Metabolic Disease) 05/2024 - 10/2015
10	Prediabetic State (Prediabetes) 04/2024 - 05/2015
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 07/2009
10	Weight Gain 01/2017 - 10/2004
9	Dyslipidemias (Dyslipidemia) 12/2022 - 01/2010
9	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 01/2013
9	Hyperinsulinism (Hyperinsulinemia) 01/2020 - 03/2002
9	Hyperlipidemias (Hyperlipidemia) 01/2020 - 03/2003
8	Chronic Pancreatitis 10/2017 - 09/2003
8	Atrophy 05/2017 - 06/2004
7	Liver Diseases (Liver Disease) 05/2024 - 01/2012
7	Nausea 12/2023 - 11/2005
6	Hyperplasia 11/2022 - 04/2003
5	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2024 - 10/2013
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2023 - 10/2017
5	Fatty Liver 01/2023 - 01/2019
5	Morbid Obesity 01/2020 - 11/2003
5	Intestinal Failure 05/2017 - 11/2006
4	Long QT Syndrome 10/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

241	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 03/2002
161	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2024 - 01/2002
122	Glucagon (Glukagon)FDA Link 05/2024 - 03/2002
109	Insulin (Novolin)FDA Link 04/2024 - 03/2002
88	Hormones (Hormone)IBA 03/2024 - 03/2002
80	IncretinsIBA 01/2024 - 01/2002
48	Peptides (Polypeptides)IBA 11/2023 - 08/2002
33	Glucagon-Like Peptide-1 ReceptorIBA 03/2024 - 08/2009
31	Proteins (Proteins, Gene)FDA Link 11/2023 - 06/2004
24	CarbohydratesIBA 02/2024 - 03/2003
23	Liraglutide FDA Link 01/2024 - 01/2013
22	Metformin (Glucophage)FDA LinkGeneric 02/2024 - 01/2006
20	C-PeptideIBA 07/2023 - 05/2003
18	Amino Acids FDA Link 01/2024 - 04/2007
17	Triglycerides (Triacylglycerol)IBA 05/2022 - 03/2003
16	Hypoglycemic Agents (Hypoglycemics)IBA 01/2024 - 09/2004
15	Blood Glucose (Blood Sugar)IBA 12/2022 - 03/2004
15	Dipeptidyl-Peptidase IV InhibitorsIBA 10/2022 - 01/2006
14	Glucagon Receptors (Glucagon Receptor)IBA 05/2024 - 01/2016
14	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2022 - 01/2002
13	LipidsIBA 01/2023 - 01/2004
12	Glucagon-Like Peptide-1 Receptor AgonistsIBA 04/2023 - 01/2008
11	Collagen Type I (Type I Collagen)IBA 07/2023 - 12/2003
10	Bile Acids and Salts (Bile Acids)IBA 03/2024 - 09/2009
10	Glucagon-Like Peptides (Enteroglucagon)IBA 11/2023 - 12/2003
10	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 03/2003
10	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 11/2020 - 05/2002
9	EnzymesIBA 10/2023 - 11/2003
8	gastric inhibitory polypeptide receptorIBA 11/2023 - 01/2002
8	Sitagliptin Phosphate (Januvia)FDA Link 10/2022 - 11/2006
8	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 03/2004
8	VildagliptinIBA 11/2016 - 01/2007
7	Peptide YYIBA 01/2023 - 02/2005
7	Glucagon-Like Peptide 2IBA 01/2019 - 11/2006
6	Alanine (L-Alanine)FDA Link 10/2023 - 01/2018
6	C-Reactive ProteinIBA 01/2023 - 03/2004
6	Biomarkers (Surrogate Marker)IBA 01/2023 - 08/2008
6	LinagliptinIBA 01/2022 - 01/2010
6	Exenatide (Byetta)FDA Link 01/2022 - 11/2005
6	Antipsychotic Agents (Antipsychotics)IBA 08/2019 - 01/2010
6	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 05/2018 - 12/2003
5	Proglucagon (Glucagon Precursors)IBA 05/2024 - 04/2008
5	Butyrates (Butyrate)IBA 01/2023 - 07/2004
5	Volatile Fatty AcidsIBA 01/2023 - 01/2017
5	LeptinIBA 10/2022 - 01/2008
5	GhrelinIBA 10/2022 - 01/2008
5	Nonesterified Fatty Acids (NEFA)IBA 03/2022 - 06/2003
5	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 01/2022 - 09/2018
5	Whey ProteinsIBA 01/2021 - 07/2009
5	Glutamine (L-Glutamine)FDA Link 01/2018 - 01/2009
5	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 11/2016 - 01/2008
5	Arginine (L-Arginine)FDA Link 04/2013 - 05/2010
4	glimepiride (Amarel)FDA LinkGeneric 01/2022 - 07/2014

Therapy/Procedure

40	Gastric Bypass (Roux-en-Y Gastric Bypass) 12/2023 - 02/2009
37	Therapeutics 11/2023 - 09/2003
15	Glycemic Control 04/2023 - 08/2007
10	Intravenous Infusions 03/2024 - 12/2003
9	Caloric Restriction 10/2023 - 02/2010
8	High-Protein Diet 02/2024 - 01/2018
8	Bariatric Surgery 12/2023 - 02/2014
7	Gastrectomy 03/2023 - 07/2007
7	Parenteral Nutrition 11/2017 - 06/2004
7	Total Parenteral Nutrition 05/2017 - 06/2004
5	Drug Therapy (Chemotherapy) 11/2023 - 10/2008
5	Subcutaneous Injections 01/2022 - 09/2003
4	Operative Surgical Procedures 01/2022 - 03/2004
4	Aftercare (After-Treatment) 01/2022 - 07/2007